Pharmacogenomic Testing vs 23andMe: Understanding Your Options
8 min read · Last updated: April 2026 · DecodeMyBio Editorial Team
23andMe is a consumer DNA test. Clinical pharmacogenomic testing is a medical test. They were built for different purposes — but there's meaningful overlap in the genetic data they produce. If you've already taken 23andMe, your raw data can be reanalyzed for pharmacogenomic insights through services like DecodeMyBio. This page explains how these two approaches compare and when each one makes sense.
Already have 23andMe or AncestryDNA data?
Skip the wait and cost of clinical testing. DecodeMyBio analyzes your existing raw data for pharmacogenomic insights mapped to published CPIC clinical guidelines — 19 genes, 150+ drug-gene interactions, results in minutes.
What Is Clinical Pharmacogenomic Testing?
Clinical pharmacogenomic testing is purpose-built for one thing: identifying how your genes affect your response to medications. These are medical tests ordered by a doctor or prescribing clinician, processed in a certified laboratory, and delivered as a clinical report.
The major providers include:
- GeneSight (Myriad Genetics) — 15 genes, 60+ psychotropic medications, $330 self-pay
- Genomind Professional PGx Express — 26 genes, 130+ neuropsychiatric medications, $599 self-pay
- OneOme RightMed — broad panel covering multiple therapeutic areas
- Hospital-based labs — many academic medical centers now offer in-house PGx panels, often integrated with the electronic health record
These tests use laboratory methods (targeted sequencing, real-time PCR, or similar) that provide thorough allele coverage for the specific genes they test. They can detect rare variants, structural changes like gene deletions or duplications, and novel mutations that chip-based genotyping would miss.
The trade-off: clinical testing requires a provider order, may involve insurance complexities, and typically costs $250–2,000+ depending on the test and coverage. For more on pricing, see our pharmacogenomic testing cost guide.
What Does 23andMe Actually Test?
23andMe is a direct-to-consumer genotyping service. You order a kit, provide a saliva sample, and receive results for ancestry composition, health predispositions, carrier status, and wellness traits. The test uses a genotyping chip (microarray) that reads approximately 600,000+ specific positions across your genome.
23andMe was not designed for pharmacogenomics. It does include a limited pharmacogenomics section in its health reports (covering a handful of drug-gene pairs), but the real value for PGx lies in the raw data file you can download. That file contains genotype calls for hundreds of thousands of variants — including many pharmacogene SNPs that 23andMe doesn't surface in its own reports.
When a service like DecodeMyBio analyzes your 23andMe raw data, it extracts pharmacogene variants, assigns star alleles and diplotypes, determines your metabolizer phenotype for each gene, and maps the results to published CPIC clinical guidelines. The output is a pharmacogenomic report — not an ancestry report.
The Key Differences
Information sourced from public materials as of April 2026. Verify current details directly with each provider.
| Feature | Clinical PGx Testing | 23andMe + Reanalysis |
|---|---|---|
| Primary purpose | Medication guidance | Ancestry + traits (PGx via reanalysis) |
| Ordering | Doctor order required | Direct consumer + self-service upload |
| Cost | $250–2,000+ (varies by test & insurance) | $99–199 kit + $19–59 analysis (or $19–59 if you already have data) |
| PGx capability | Built-in — the whole point | Requires third-party reanalysis (e.g., DecodeMyBio) |
| Total cost for PGx insights | $250–2,000+ | $19–59 (if you already have data) |
| Gene coverage method | Full sequencing per gene | Chip-based tag SNPs (common variants) |
| Rare allele detection | Yes | Limited |
| Turnaround | Days to weeks | Minutes (if data already available) |
| Additional insights | PGx only | Ancestry, health traits, plus PGx via reanalysis |
Can 23andMe Replace Clinical Pharmacogenomic Testing?
The honest answer: partially, and it depends on what you need.
Where 23andMe data analysis performs well
For the most common clinically relevant drug-gene interactions, 23andMe raw data analysis identifies the same metabolizer phenotypes as clinical testing. The common alleles that affect the majority of the population — CYP2D6 *3, *4, *5, *6, *41; CYP2C19 *2, *3, *17; CYP2C9 *2, *3 — are well-represented on consumer genotyping chips. If your goal is awareness of your metabolizer status across key pharmacogenes, reanalysis of existing data is a practical and cost-effective approach.
Where clinical testing is stronger
Clinical pharmacogenomic tests provide more complete allele coverage per gene. This matters most for complex genes like CYP2D6, which has over 100 known alleles including structural variants (gene deletions, duplications, hybrid genes) that chip-based genotyping cannot fully resolve. If your clinical situation requires certainty about rare alleles, clinical testing is more thorough.
The practical middle ground
Raw data analysis works well as a first step or screening tool. It surfaces the most clinically relevant drug-gene interactions at low cost and with no barriers. If something significant appears (e.g., poor metabolizer status for a gene relevant to your current medications), you and your clinician can decide whether confirmatory clinical testing is warranted.
For more on the strengths and limitations of consumer genotyping data, see our limitations page and methodology.
When to Choose Each Approach
Here is a practical decision framework:
Start with 23andMe data reanalysis if:
- You already have 23andMe or AncestryDNA data (or are willing to get it for other reasons like ancestry)
- You want a low-cost, immediate overview of your pharmacogenomic profile
- You're interested in multiple areas beyond psychiatry — pain management, nutrition, cannabis metabolism, celiac risk
- You want to understand your genetics before committing to a more expensive clinical test
- You prefer at-home testing without a doctor visit
Choose clinical PGx testing if:
- Your doctor recommends it and insurance covers the cost
- You need definitive results for a critical medication decision (e.g., treatment-resistant depression, high-risk drug with narrow therapeutic window)
- You want results integrated directly into your medical record
- You don't have existing DNA data and want a single test focused purely on medications
- Your clinical situation involves genes with many rare alleles (particularly CYP2D6 structural variants)
Consider both if:
- You want the breadth of consumer data analysis now, plus the depth of clinical testing when clinically indicated
- You start with reanalysis and find results that your clinician wants to confirm with a clinical-grade test
Already have 23andMe or AncestryDNA? Start here.
Upload your raw data file and get pharmacogenomic insights in minutes. See your metabolizer phenotypes mapped to CPIC guidelines across 19 genes and 150+ drug-gene interactions — from $19.
Frequently Asked Questions
Is 23andMe a pharmacogenomic test?
No. 23andMe is a consumer genotyping test designed for ancestry and health traits. However, its raw data file contains many pharmacogene variants that can be extracted and analyzed by third-party services like DecodeMyBio to produce pharmacogenomic reports mapped to published CPIC guidelines.
How much does clinical PGx testing cost vs 23andMe reanalysis?
Clinical pharmacogenomic tests typically cost $250–2,000+ depending on the provider and insurance coverage. If you already have 23andMe data, reanalysis through DecodeMyBio costs $19–59 per report. See our pharmacogenomic testing cost guide for detailed pricing.
Can 23andMe raw data analysis replace clinical PGx testing?
For screening and awareness of common drug-gene interactions, yes. For clinical decisions requiring full allele coverage (especially complex genes like CYP2D6), clinical testing is more complete. Raw data analysis works best as a first step or complement to clinical testing — not necessarily a full replacement in all situations.
Which clinical pharmacogenomic tests are available?
Major providers include GeneSight (Myriad Genetics, 15 genes, $330 self-pay), Genomind Professional PGx Express (26 genes, $599 self-pay), OneOme RightMed, and hospital-based laboratory panels. All require a doctor or clinician order.